Medical Condition News

RSS

FDA grants approval for Dyax' KALBITOR for treating HAE patients

Dyax Corp. announced today that the U.S. Food and Drug Administration (FDA) has granted approval for KALBITOR® (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older.

2 Dec 2009

Middle-aged women more likely to show signs of obesity

A small study of middle-aged women finds that "guilt-ridden dieters," impulsive eaters and those too busy to focus on food are the most likely to show signs of obesity.

2 Dec 2009

Obesity research may be misrepresented by scientists working on bias topics, says UAB study

A new study by researchers at the University of Alabama at Birmingham (UAB) School of Public Health shows that obesity research may be misrepresented by scientists operating with particular biases on topics related to weight, nutrition and the food industry.

1 Dec 2009

CRO to run CEL-SCI's upcoming Phase III clinical trial

CEL-SCI Corporation, a late-stage oncology company and a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases, announced today that it has retained the services of an international Contract Research Organization (CRO) to run CEL-SCI's upcoming Phase III clinical trial in advanced primary head and neck cancer with the Company's lead product candidate, Multikine®.

1 Dec 2009

Bonn scientists discover a promising new approach to combat obesity

Brown adipose tissue is different from white fat pads. It contains loads of mitochondria, miniature power stations which among other things can 'burn' fat. In doing this, they normally generate a voltage similar to that of a battery, which then provides energy for cellular processes.

1 Dec 2009

ASH to host annual High School Student Symposium at New Orleans Marriott

The American Society of Hematology (ASH) will host its annual High School Student Symposium at the New Orleans Marriott on Thursday, December 3, at 8:00 a.m. CST.

1 Dec 2009

Acceleron Pharma announces study results of its ACE-011 and ACE-536 blood forming agents

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, today announced that results from preclinical and clinical studies of two, novel blood forming agents, ACE-011 and ACE-536, will be presented at the 51st Annual Meeting of the American Society of Hematology at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

1 Dec 2009

Teva Pharmaceutical Industries submits a BLA for its G-CSF XM02

Teva Pharmaceutical Industries Ltd., today announced the submission of a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for XM02, a granulocyte colony-stimulating factor (G-CSF) for the reduction in the duration of severe neutropenia and the incidence of febrile neutropenia in patients treated with established myelosuppressive chemotherapy for cancer.

1 Dec 2009

Calistoga Pharmaceuticals to present data on its CAL-101 inhibitor at the 51st ASH meeting

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced that clinical and preclinical data supporting the role of CAL-101, an oral, p110δ(delta) selective PI3K inhibitor in patients with hematologic malignancies, will be featured in two oral presentations at the upcoming 51st American Society of Hematology (ASH) Annual Meeting taking place in New Orleans, LA.

1 Dec 2009

Human-animal bond offers significant benefits

A pet owner knows the enormous joy and comfort that an animal can provide, especially in troubled times. Most pets are considered important members of the family and irreplaceable companions.

1 Dec 2009

New figures show steady decline in European cancer deaths, but variations exist between gender and countries

New figures show there was a steady decline in cancer deaths in the European Union between 1990-1994 and 2000-2004.

1 Dec 2009

Pfizer, Protalix team up to develop and market plant-based enzyme for Gaucher’s disease treatment

Pfizer and Protalix (NYSE-Amex: PLX) today announced that they have entered into an agreement to develop and commercialize taliglucerase alfa, a plant-cell expressed form of glucocerebrosidase (GCD) in development for the potential treatment of Gaucher’s disease.

1 Dec 2009

Bayer Schering Pharma to develop new BiTE antibody for treatment of solid tumors

Micromet, Inc., a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases today announced that Bayer Schering Pharma AG has exercised its option under the option, collaboration and license agreement entered into on January 12, 2009 to develop a new BiTE antibody for the treatment of solid tumors.

1 Dec 2009

Majority of Canadians join global charity event to raise awareness on prostate cancer

Movember, the month formerly known as November, is proud to share that 35,068 Canadians across the country joined the movement by growing a Mo (slang for moustache) and supporting men's health issues. This year over $6.3 million has been raised for Prostate Cancer Canada, with funds continuing to pour in.

1 Dec 2009

Cancer patient's chances of surviving for at least a year varies depending on where they live

CANCER RESEARCH UK is calling on the government and PCTs across the country to act urgently after shocking new figures, out today (Tuesday), reveal a cancer patient's chances of surviving for at least a year varies hugely depending on where they live.

1 Dec 2009

Study examines role of low-oxygen exposure in heart failure patients

Distance runners who live at high altitudes with low oxygen levels are known to improve their performance during races in areas that are at sea level. Can heart failure patients, who suffer from fatigue, improve their exercise performance by staying in a tent-like, high-altitude simulator?

1 Dec 2009

Guidelines for using videoconferencing for mental health services approved

The American Telemedicine Association (ATA) announced the availability of formal practice guidelines for the use of videoconferencing for the delivery of mental health services.

1 Dec 2009

D-ATLAS to map the prevalence and costs associated with type 2 diabetes launched

Pinpointing the prevalence and cost of type 2 diabetes and now, the prevalence of obesity (Body Mass Index [BMI] of 30 or greater), is just a mouse click away thanks to a Web-based tool developed by the National Minority Quality Forum (NMQF).

1 Dec 2009

Type 1 diabetes youth have abnormal insulin resistance that may increase risk of cardiovascular disease

According to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM), youth with type 1 diabetes have now been found to have abnormal insulin resistance. Having abnormal insulin resistance appears to negatively affect heart, blood vessel and exercise function in this population.

1 Dec 2009

Framework for Canada's national mental health strategy released

In a first step toward changing Canada's status as the only G8 country without a mental health strategy, the Mental Health Commission of Canada (MHCC) today released the framework for Canada's national strategy.

1 Dec 2009

Medical Condition News

FDA grants approval for Dyax' KALBITOR for treating HAE patients

Middle-aged women more likely to show signs of obesity

Obesity research may be misrepresented by scientists working on bias topics, says UAB study

CRO to run CEL-SCI's upcoming Phase III clinical trial

Bonn scientists discover a promising new approach to combat obesity

ASH to host annual High School Student Symposium at New Orleans Marriott

Acceleron Pharma announces study results of its ACE-011 and ACE-536 blood forming agents

Teva Pharmaceutical Industries submits a BLA for its G-CSF XM02

Calistoga Pharmaceuticals to present data on its CAL-101 inhibitor at the 51st ASH meeting

Human-animal bond offers significant benefits

New figures show steady decline in European cancer deaths, but variations exist between gender and countries

Pfizer, Protalix team up to develop and market plant-based enzyme for Gaucher’s disease treatment

Bayer Schering Pharma to develop new BiTE antibody for treatment of solid tumors

Majority of Canadians join global charity event to raise awareness on prostate cancer

Cancer patient's chances of surviving for at least a year varies depending on where they live

Study examines role of low-oxygen exposure in heart failure patients

Guidelines for using videoconferencing for mental health services approved

D-ATLAS to map the prevalence and costs associated with type 2 diabetes launched

Type 1 diabetes youth have abnormal insulin resistance that may increase risk of cardiovascular disease

Framework for Canada's national mental health strategy released

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News